73.90
2.18%
+1.58
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals, Inc. stock is currently priced at $73.90, with a 24-hour trading volume of 140.84K.
It has seen a +2.18% increased in the last 24 hours and a -1.11% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $71.96 pivot point. If it approaches the $74.91 resistance level, significant changes may occur.
Previous Close:
$72.32
Open:
$73.53
24h Volume:
140.84K
Market Cap:
$1.33B
Revenue:
$131.31M
Net Income/Loss:
$52.15M
P/E Ratio:
51.32
EPS:
1.44
Net Cash Flow:
$-4.27M
1W Performance:
+4.72%
1M Performance:
-1.11%
6M Performance:
+36.88%
1Y Performance:
-2.03%
Ligand Pharmaceuticals, Inc. Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals, Inc.
Sector
Industry
Phone
858-550-7500
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA
Ligand Pharmaceuticals, Inc. Stock (LGND) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-14-21 | Resumed | Stephens | Overweight |
Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
Oct-06-20 | Initiated | Barclays | Overweight |
Mar-24-20 | Downgrade | Argus | Buy → Hold |
Mar-10-20 | Initiated | Guggenheim | Neutral |
Feb-06-20 | Initiated | The Benchmark Company | Buy |
Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
Jun-11-19 | Initiated | Barclays | Equal Weight |
May-03-19 | Reiterated | H.C. Wainwright | Buy |
Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
Sep-11-18 | Reiterated | Argus | Buy |
Aug-17-18 | Initiated | Goldman | Neutral |
Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
Jun-21-18 | Initiated | Argus | Buy |
Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
Sep-05-17 | Resumed | H.C. Wainwright | Buy |
Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
Mar-11-16 | Initiated | Sidoti | Buy |
Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals, Inc. Stock (LGND) Latest News
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Zacks Investment Research
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Zacks Investment Research
Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
Zacks Investment Research
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Zacks Investment Research
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
Zacks Investment Research
Ligand Pharmaceuticals, Inc. Stock (LGND) Financials Data
Ligand Pharmaceuticals, Inc. (LGND) Revenue 2024
LGND reported a revenue (TTM) of $131.31 million for the quarter ending December 31, 2023, a -33.09% decline year-over-year.
Ligand Pharmaceuticals, Inc. (LGND) Net Income 2024
LGND net income (TTM) was $52.15 million for the quarter ending December 31, 2023, a +256.33% increase year-over-year.
Ligand Pharmaceuticals, Inc. (LGND) Cash Flow 2024
LGND recorded a free cash flow (TTM) of -$4.27 million for the quarter ending December 31, 2023, a -103.56% decrease year-over-year.
Ligand Pharmaceuticals, Inc. (LGND) Earnings per Share 2024
LGND earnings per share (TTM) was $2.90 for the quarter ending December 31, 2023, a +246.46% growth year-over-year.
Ligand Pharmaceuticals, Inc. Stock (LGND) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
KOZARICH JOHN W | Director |
Apr 24 '24 |
Option Exercise |
39.35 |
2,893 |
113,840 |
42,523 |
Davis Todd C | Chief Executive Officer |
Mar 25 '24 |
Option Exercise |
57.39 |
16,015 |
919,147 |
120,160 |
Aryeh Jason | Director |
Mar 05 '24 |
Option Exercise |
39.35 |
2,893 |
113,840 |
74,422 |
Sabba Stephen L | Director |
Mar 05 '24 |
Option Exercise |
0.00 |
2,893 |
0 |
30,819 |
Sabba Stephen L | Director |
Mar 05 '24 |
Sale |
74.30 |
1,893 |
140,650 |
28,926 |
Espinoza Octavio | Chief Financial Officer |
Feb 28 '24 |
Option Exercise |
56.62 |
1,264 |
71,564 |
29,895 |
Espinoza Octavio | Chief Financial Officer |
Feb 28 '24 |
Sale |
88.46 |
140 |
12,384 |
29,755 |
Davis Todd C | CHIEF EXECUTIVE OFFICER |
Sep 22 '23 |
Buy |
59.38 |
4,000 |
237,529 |
73,090 |
KOZARICH JOHN W | Director |
May 16 '23 |
Sale |
77.20 |
4,444 |
343,081 |
38,488 |
Sabba Stephen L | Director |
May 10 '23 |
Option Exercise |
0.00 |
6,408 |
0 |
32,192 |
About Ligand Pharmaceuticals, Inc.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):